Viral load in HIV-infected children on high activity antiretroviral therapy

被引:2
作者
Resino, Salvador
Bellon, Jose M.
Antonio Leon, Juan
Resino, Rosa
Munoz-Fernandez, M. Angeles
机构
[1] Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, Madrid, Spain
[2] Hosp Virgen Rocio, Serv Enfermedades Infecciosas Pediat, Seville, Spain
来源
MEDICINA CLINICA | 2007年 / 128卷 / 02期
关键词
HIV; children; viral load; HAART; prognostic marker; VIROLOGICAL FAILURE;
D O I
10.1157/13097471
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND AND OBJECTIVE: To determine whether viral load (W prior to undetectable VL has predictive value on the re-emergence of VL (> 400 copies/ml, > 5,000 copies/ml and > 30,000 copies/ml). PATIENTS AND METHOD: Retrospective study carried out on 81 vertically human immunodeficiency virus (HIV)-infected children on antiretroviral therapy who were distributed in 3 groups according to their median value of VL one year before reaching undetectable VL: A-group: VL < 5,000 copies/ml; B-group: VL between 5,000 and 30,000 copies/ml, and C-group: VL > 30,000 copies/ml. RESULTS: During the whole follow-up period, 63 (77.8%) children had a rebound of VL > 400 copies/ml. Forty-two (51.8%) children had a rebound of VL > 5,000 copies/ml. Twenty-seven (33.3%) children had a rebound of VL > 30,000 copies/ml. HIV-children of B-group had values of hazard ratio (HR) statistically significant for a rebound of VL > 5,000 copies/ml. Moreover, HIV-children of C-group had values of HR greater and statistically significant for a rebound of VL > 500, > 5,000 and > 30,000 copies/ml. For a rebound of VL > 30,000 copies/ml, the C-group had values of RR > 12. CONCLUSIONS: High VL levels prior to undetectable VL can be a useful prognostic marker of virological failure in HIV-infected children.
引用
收藏
页码:49 / 51
页数:3
相关论文
共 10 条
[1]  
[Anonymous], 1998, MMWR Recomm Rep, V47, P1
[2]   Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel [J].
Carpenter, CCJ ;
Cooper, DA ;
Fischl, MA ;
Gatell, JM ;
Gazzard, BG ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schechter, M ;
Schooley, RT ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (03) :381-390
[3]   T cell dynamics in HIV-1 infection [J].
Douek, DC ;
Picker, LJ ;
Koup, RA .
ANNUAL REVIEW OF IMMUNOLOGY, 2003, 21 :265-304
[4]   Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain [J].
Gallego, O ;
Ruíz, L ;
Vallejo, A ;
Clotet, B ;
Leal, M ;
Soriano, V .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (10) :3865-3866
[5]   Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor [J].
Grabar, S ;
Pradier, C ;
Le Corfec, E ;
Lancar, R ;
Allavena, C ;
Bentata, M ;
Berlureau, P ;
Dupont, C ;
Fabbro-Peray, P ;
Poizot-Martin, I ;
Costagliola, D .
AIDS, 2000, 14 (02) :141-149
[6]   Prevalence and predictive value of intermittent viremia with combination HIV therapy [J].
Havlir, DV ;
Bassett, R ;
Levitan, D ;
Gilbert, P ;
Tebas, P ;
Collier, AC ;
Hirsch, MS ;
Ignacio, C ;
Condra, J ;
Günthard, HF ;
Richman, DD ;
Wong, JK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (02) :171-179
[7]   Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions [J].
Martinez-Picado, J ;
Morales-Lopetegi, K ;
Wrin, T ;
Prado, JG ;
Frost, SDW ;
Petropoulos, CJ ;
Clotet, B ;
Ruiz, L .
AIDS, 2002, 16 (06) :895-899
[8]   CD38 expression in CD8+ T cells predicts virological failure in HIV type 1-infected children receiving antiretroviral therapy [J].
Resino, S ;
Bellón, JM ;
Gurbindo, MD ;
Muñoz-Fernández, MA .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (03) :412-417
[9]   Responses to antiretroviral treatments in vertically HIV-1-infected children [J].
Resino, S ;
Bellón, JM ;
Gurbindo, D ;
Ramos, JT ;
León, JA ;
Muñoz-Fernández, MA .
MEDICINA CLINICA, 2002, 119 (19) :725-729
[10]   PENTA guidelines for the use of antiretroviral therapy, 2004 [J].
Sharland, M ;
Blanche, S ;
Castelli, G ;
Ramos, J ;
Gibb, D .
HIV MEDICINE, 2004, 5 :61-86